Papers
6
Total Citations
71
H-Index
4
About
Shancheng Ren is a urological surgeon and clinical researcher whose work sits at the intersection of robotic surgery, radiation oncology, and prostate cancer management. His most influential contribution — a 2023 systematic review and meta-analysis comparing robotic-assisted radical prostatectomy (RARP) with laparoscopic radical prostatectomy — stands as the first study to separately pool randomised and non-randomised evidence on this question, earning 49 citations and providing a critical evidence base for surgeons worldwide. Ren has also pioneered innovative multimodal approaches to high-risk disease, designing and leading phase I/II clinical trials investigating neoadjuvant radiohormonal therapy prior to radical prostatectomy for locally advanced and oligometastatic prostate cancer — work that challenges conventional treatment sequencing and opens new avenues for delaying castration resistance. His technical contributions include refining extraperitoneal single-site robotic prostatectomy with extended pelvic lymph node dissection, pushing the boundaries of minimally invasive surgery. The ongoing multicenter NEAR-TOP randomised controlled trial reflects his commitment to generating high-quality evidence for oligometastatic disease. Across his portfolio, Ren demonstrates a consistent drive to rigorously evaluate and advance surgical and combinatorial therapies for one of oncology's most prevalent cancers.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6